Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Jefferies Cuts Bio-Reference Laboratories to Hold

From Standard & Poor's Equity Research

Jefferies downgraded Bio-Reference Laboratories (BRLI) to hold from buy, noting the stock's valuation.

Analyst Arthur Henderson says he remains bullish on the company's business prospects and there could be modest upside to earnings per share (EPS) in the second half of 2006. Nonetheless, he believes a recent run-up in the stock has left little upside at its current valuation. He notes that the stock surged since its addition to the Investor's Business Daily 100 Top-Rated Stocks in mid-June. He expects the company to build on its strong second quarter financial performance, as well as post improving cash flows in the third and fourth quarters. However, he does not believe this upside will be sufficient to support expansion in the current valuation. He maintains his $22 stock price target.

blog comments powered by Disqus